arrow
K

Karl Wallendszus

University of Oxford
H指数:24
被引数:4,241

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

HPS-4/TIMI 65/ORION-4:一项双盲、随机、安慰剂对照试验,评估依洛尤单抗对动脉粥样硬化性心血管疾病患者临床结局的影响:试验设计、招募和基线特征

2026-09-010
PRE
Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial

非诺贝特和糖尿病成人视网膜病变的进展:随机安慰剂对照的LENS试验

2026-05-010
PRE
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial

非诺贝特与标准护理在延缓糖尿病视网膜病变进展中的成本效益:一项基于LENS试验数据的经济学评估

2025-07-030
OAAI
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
2021-12-1531
OAAI
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
2018-10-18803
OAAI
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
2018-10-18544
OAAI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

辛伐他汀联合依泽替米贝降低LDL胆固醇对慢性肾脏病患者的影响 (心脏和肾脏保护研究): 一项随机安慰剂对照试验

LANCET
IF88.5
2011-06-011.9K
OAAI
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

在12 064名心肌梗死幸存者中,每天使用80 mg辛伐他汀与20 mg辛伐他汀强化降低LDL胆固醇: 一项双盲随机试验

LANCET
IF88.5
2010-11-01460
OAAI